Lupus & antiphospholipid syndrome
Real-world efficacy of belimumab in systemic lupus erythematosus: a prospective cohort from a single centre in China
An erratum to this article was published (Rheumatology (Oxford), 1 Dec 2025 ↗)
Authors' conclusion
Our data supported the efficacy of belimumab in Chinese SLE patients in a real-life setting.
Study context
- Population
- Chinese SLE patients taking belimumab on background standard-of-care (SoC), enrolled July 2021 to December 2022median follow-up 12 months
- Participants
- 123 patients
- Exposure
- Belimumab on background SoC; newly diagnosed vs relapsed vs refractory SLE; newly diagnosed with SoC alone as comparator
- Newly diagnosedn = 33
- Relapsedn = 32
- Refractoryn = 58
- Outcome
- SRI-4 response
Methodological detailssingle-centre, real-world, consecutive enrolment
- Single-centre
- Real-world
- Consecutive enrolment
Main finding
As reported in the abstract
SRI-4 response, all belimumab patients
- SRI-4 response at 3 months
- 55.77%
- SRI-4 response at 6 months
- 56.63%
- SRI-4 response at 9 months
- 63.24%
- SRI-4 response at 12 months
- 63.64%
- SRI-4 response at 18 months
- 57.14%
Observational data: associations, not effects.
Further findings
Serological parameters (anti-dsDNA, C3/C4), SLEDAI-2K and daily prednisone
- Improved overall and in each group
- Newly diagnosed had the highest SRI-4 rate and greatest improvement in serological parameters and SLEDAI-2K
Cumulative prednisone intake, newly diagnosed belimumab vs SoC alone
- Significantly decreased with belimumab
Original publication
Real-world efficacy of belimumab in systemic lupus erythematosus: a prospective cohort from a single centre in China. Rheumatology (Oxford). Published 27 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →